Catalyst
Slingshot members are tracking this event:
Axovant (AXGT) Announces 12-month Data on AXO-Lenti-PD
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
AXGT |
|
|
Additional Information
• AXO-Lenti-PD was observed to be well-tolerated with no serious adverse events attributable to the gene therapy.
• Improvement in the UPDRS Part III “OFF” score in the first cohort exhibited evidence of dose response when compared to the low (n=3), medium (n=6), and high (n=6) dose cohorts of ProSavin that were previously evaluated in a separate Phase 1/2 study at 12 months
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 13, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Axo-lenti-pd, Gene Therapy